Basic information |
Metabolite name | 5-Hydroxy-L-tryptophan |
HMDB0000472 | |
C00643 | |
144 | |
Synonyms | 5-hydroxytryptophan |
No. of studies | 20 |
Relationship between 5-Hydroxy-L-tryptophan and depression (count: 20) |
Study | Study Type | Comparison groups | Tissue | Organism | Up/Down regulated |
Study M1008 | Type2 | CCFM1025 group vs. placebo group | Faece | Human | Up |
Study M1040 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
Study M1040 | Type2 | CUMS + Roseburia inulinivorans group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
Study M1040 | Type2 | CUMS + Bacteroides uniformis group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
Study M1045 | Type1 | anxiety and depression group vs. control group | Plasma | Human | Up |
Study M1087 | Type1 | CSDS group vs. control group | Faece | C57BL/6 mouse | Down |
Study M1090 | Type2 | CUMS + hyperbaric oxygen treatment group vs. CUMS group | Plasma | BALb/c mouse | Down |
Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Brain | Sprague-Dawley rat | Down |
Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Brain | Sprague-Dawley rat | Down |
Study M147 | Type2 | FSL sustained fluoxetine group vs. FSL sustained control group | Cerebellum | Sprague-Dawley rat | Down |
Study M147 | Type2 | FSL sustained vortioxetine group vs. FSL sustained control group | Cerebellum | Sprague-Dawley rat | Down |
Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Brain | Sprague-Dawley rat | Down |
Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Cerebellum | Sprague-Dawley rat | Down |
Study M147 | Type3 | SD sustained vortioxetine group vs. SD sustained control group | Cerebellum | Sprague-Dawley rat | Down |
Study M147 | Type3 | SD sustained fluoxetine group vs. SD sustained control group | Brain | Sprague-Dawley rat | Down |
Study M151 | Type1 | Female FSL group vs. Female FRL group | Brain | Sprague-Dawley rat | Down |
Study M516 | Type1 | SMG-treated group vs. control group | Urine | Sprague-Dawley rat | Down |
Study M583 | Type1 | PSD group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
Study M583 | Type2 | PSD group, after vs. before fluoxetine treatment | Hippocampus | Sprague-Dawley rat | Up |
Study M594 | Type1 | CRS group vs. control group | Entorhinal cortex | C57BL/6 mouse | Up |
Study M598 | Type1 | MS group vs. control group | Brain | Sprague-Dawley rat | Up |
Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
Study M672 | Type1 | SMG group vs. control group | Urine | Sprague-Dawley rat | Down |
Study M701 | Type1 | MDD group vs. control group | Plasma | Human | Down |
Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Hippocampus | C57BL/6J mouse | Down |
Study M722 | Type2 | CUMS-transferred group + 5-hydroxytryptophan group vs. CUMS-transferred group | Hippocampus | C57BL/6J mouse | Up |
Study M722 | Type2 | CUMS-transferred group + 5-hydroxytryptophan group vs. CUMS-transferred group | Serum | C57BL/6J mouse | Up |
Study M777 | Type1 | HFCS-MFD group vs. control group | Serum | C57Bl/6J mouse | Down |
Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Up |
Study M920 | Type1 | anhedonia-susceptible group vs. control grou | Nucleus accumbens | Sprague-Dawley rat | Up |
Study M980 | Type1 | CMS group vs. control group | Olfactory bulb | C57BL/6J mouse | Down |